Yüklüyor......
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
The treatment landscape of metastatic renal cell carcinoma (mRCC) has been transformed with the advent of antiangiogenics, notably tyrosine kinase inhibitors (TKIs) targeting vascular endothelial growth factor receptor (VEGFR), and immune checkpoint inhibitors (ICIs). Both treatment options have imp...
Kaydedildi:
| Yayımlandı: | Ther Adv Med Oncol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
SAGE Publications
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7081462/ https://ncbi.nlm.nih.gov/pubmed/32215057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920907504 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|